Rev Esp Quimioter 2021;34(Suppl.1):57-59

Antiviral therapy and immunotherapy of COVID-19


Published: 30 September 2021


The pharmacological treatment of COVID-19 has evolved in the months since the description of the disease. Published observational studies and, above all, clinical trials have highlighted drugs that are useful as well as ruled out any benefit from other drugs used at the beginning of the pandemic. The pathogenesis of the disease has suggested that patients may benefit from the administration of both antivirals, mainly in the earliest stages, and anti-inflammatory/immunomodulatory medications in more advanced stages. We present a short review of the drugs used and under investigation for the treatment of COVID-19.

Rev Esp Quimioter 2021; 34(Suppl. 1):57-59 [Full-text PDF]